MedTrace Logo

Glutamine Supplementation and Short-term Mortality in Covid-19

NCT04909905 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2021-11-05

No results posted yet for this study

Summary

The aim of this study is to investigate the effect of parenteral L-Glutamine supplementation added to enteral nutrition on short-term ICU mortality (7 days) in Covid-19 diseased patients.

Conditions

  • Covid19

Interventions

DIETARY_SUPPLEMENT

Standard enteral nutrition

Standard enteral nutrition according to ICU nutrition protocol for 7 days

COMBINATION_PRODUCT

Glutamine

Intravenous glutamine supplementation to enteral nutrition in a dose of dose of glutamine of 0.4 g/kg/day for 7days

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Omar Soliman, MD · Omar makram

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-30
Primary Completion
2021-10-25
Completion
2021-10-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04909905 on ClinicalTrials.gov